316 related articles for article (PubMed ID: 11524817)
21. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
Giorgetti A; Volterrani D; Mariani G
Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
[TBL] [Abstract][Full Text] [Related]
22. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
[TBL] [Abstract][Full Text] [Related]
23. [Current status of nuclear medicine clinical application of FDG-PET for cancer diagnosis. Head and neck cancer].
Nakasone Y; Mogi K; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):258-64. PubMed ID: 12073631
[TBL] [Abstract][Full Text] [Related]
24. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
25. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Esophageal cancer].
Noboru O
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):265-9. PubMed ID: 12073632
[TBL] [Abstract][Full Text] [Related]
26. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
27. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
28. Anatomolecular imaging with 2-deoxy-2-[18F]fluoro-D-glucose: bench to outpatient center.
Wahl RL
Mol Imaging Biol; 2003; 5(2):49-56. PubMed ID: 14499144
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of tumor metabolism using FDG-PET imaging.
Weber WA; Schwaiger M; Avril N
Nucl Med Biol; 2000 Oct; 27(7):683-7. PubMed ID: 11091112
[TBL] [Abstract][Full Text] [Related]
31. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
Kostakoglu L; Hardoff R; Mirtcheva R; Goldsmith SJ
Radiographics; 2004; 24(5):1411-31. PubMed ID: 15371617
[TBL] [Abstract][Full Text] [Related]
32. [Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
Borbély K; Németh Z; Kásler M
Magy Onkol; 2014 Mar; 58(1):24-31. PubMed ID: 24712003
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
34. [Current status of nuclear medicine clinical application of FDG-PET for cancer diagnosis. Lung cancer].
Murakami K; Nawano S; Ikeda H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):252-7. PubMed ID: 12073630
[TBL] [Abstract][Full Text] [Related]
35. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.
Sève P; Billotey C; Broussolle C; Dumontet C; Mackey JR
Cancer; 2007 Jan; 109(2):292-9. PubMed ID: 17167760
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography imaging in evaluation of cancer patients.
Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
[TBL] [Abstract][Full Text] [Related]
37. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography: clinical applications in oncology. Part 1.
Kumar R; Nadig MR; Chauhan A
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
[TBL] [Abstract][Full Text] [Related]
39. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.
Shreve PD; Anzai Y; Wahl RL
Radiographics; 1999; 19(1):61-77; quiz 150-1. PubMed ID: 9925392
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of FDG PET.
Otsuka H; Graham M; Kubo A; Nishitani H
J Med Invest; 2004 Feb; 51(1-2):14-9. PubMed ID: 15000251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
